IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
Rhea-AI Summary
IDEAYA (NASDAQ: IDYA) will release topline results from the Phase 2/3 OptimUM-02 trial on Monday, April 13, 2026 at 8:00 a.m. ET. The trial evaluates darovasertib plus crizotinib in first-line HLA*A2-negative metastatic uveal melanoma.
A joint IDEAYA and Servier pre-market release will be followed by a conference call and webcast; a replay will be available on IDEAYA's website for 30 days.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – IDYA
On the day this news was published, IDYA gained 7.61%, reflecting a notable positive market reaction. Argus tracked a peak move of +16.0% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $189M to the company's valuation, bringing the market cap to $2.68B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves (e.g., DNLI -0.41%, BLTE +2.57%, TVTX +1.19%), and the momentum scanner reports no coordinated sector move, indicating this scheduled Phase 2/3 readout is primarily stock-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 06 | Phase 1 trial start | Positive | -1.2% | First-patient-in for Phase 1 IDE574 KAT6/7 inhibitor solid tumor trial. |
| Mar 30 | Combination trial start | Positive | +3.3% | First-patient-in for IDE849 and IDE161 Phase 1 combination in DLL3 tumors. |
| Mar 27 | Inducement option grants | Neutral | -5.1% | Inducement stock options totaling 49,000 shares to new employees. |
| Mar 18 | Conference presentations | Positive | -2.8% | AACR 2026 poster abstracts for multiple Phase 1 programs announced. |
| Mar 09 | Phase 1 trial start | Positive | +5.7% | First-patient-in for IDE892 PRMT5 inhibitor and MTAP/CDKN2A updates. |
Recent clinically focused updates often saw mixed to negative next-day price reactions, even when news described pipeline progress.
Over the last month, IDEAYA issued multiple pipeline and corporate updates. Three Phase 1 “first-patient-in” clinical trial announcements on Mar 9, Mar 30, and Apr 6 produced varied 24-hour moves from -1.22% to +5.69%. News on stock option and inducement grants in late March saw negative reactions of -5.08% and -2.8%. Against this backdrop of active development across programs, today’s scheduled Phase 2/3 topline darovasertib readout represents a more advanced, potentially pivotal catalyst.
Market Pulse Summary
The stock moved +7.6% in the session following this news. A strong positive reaction aligns with the significance of a Phase 2/3 registrational readout for darovasertib in metastatic uveal melanoma. The stock previously showed mixed responses to earlier-stage updates, with 24-hour moves from -5.08% to +5.69%, so a larger move around topline data could reflect the higher stakes. Investors would also weigh recent insider net buying of 50,000 shares and the company’s extensive late-stage pipeline.
Key Terms
phase 2/3 medical
registrational trial medical
metastatic uveal melanoma medical
hla*a2-negative medical
AI-generated analysis. Not financial advice.
Conference Call and Webcast Information
The webcast registration information can be accessed using this link or by visiting the Events section of the IDEAYA website. A replay of the webcast will be available on IDEAYA's website for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. IDEAYA's corporate presentation is available on its website: https://ir.ideayabio.com/
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-announce-topline-results-from-phase-23-optimum-02-trial-in-metastatic-uveal-melanoma-on-monday-april-13-2026-302739365.html
SOURCE IDEAYA Biosciences, Inc.